• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login

    Investing News NetworkYour trusted source for investing success

    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Pharmaceutical Market
    Pharmaceutical News
    Pharmaceutical Stocks
    • Pharmaceutical Market
    • Pharmaceutical News
    • Pharmaceutical Stocks
    pharmaceutical investing

    Flexion Appoints New Chief Medical Officer

    Bryan Mc Govern
    Apr. 07, 2017 08:38AM PST
    Pharmaceutical Investing

    Flexion Therapeutics (NASDAQ: FLXN) appointed Dr. Yamo Deniz as its new Chief Medical Officer.

    Flexion Therapeutics (NASDAQ: FLXN) appointed Dr. Yamo Deniz as its new Chief Medical Officer.
    As quoted in the press release:

    This appointment strengthens the company’s leadership with an industry veteran who brings extensive experience leading medical and clinical development teams at major biotechnology and pharmaceutical companies.

    With the addition of Dr. Deniz, Neil Bodick, MD, PhD, co-founder of Flexion, will transition from his position as CMO and assume the role of Chief Scientific Officer. In his new capacity, Dr. Bodick will be responsible for building Flexion’s pipeline of new drug candidates and leading discovery research activities including the assessment of external opportunities and new applications for the company’s proprietary formulation technologies.

    Dr. Deniz is an allergist and immunologist by training, and prior to joining Flexion, he served as Vice President and Global Head of Medical for Rare Diseases at Sanofi-Genzyme. Previously, he held positions as Chief Medical Officer, Global Head of Medical & Pharmacovigilance and as Vice President and Global Head of Development at GE Healthcare Medical Diagnostics. Dr. Deniz also held numerous senior clinical development and leadership positions of increasing responsibilities in the Respiratory and Inflammation groups at Genentech and Roche. Dr. Deniz received his medical degree from the University of Massachusetts Medical School. He completed his residency at Long Island Jewish Medical Center and fellowship at Duke University Medical Center.

    “With his demonstrated track record of clinical development and medical affairs, Dr. Deniz is a superb addition to Flexion’s management team as we prepare for the potential approval and commercialization of Zilretta™, also known as FX006,” said Michael Clayman, MD, President and Chief Executive Officer of Flexion. “His extensive pharmaceutical R&D background will be invaluable to us as we expand Flexion into a fully integrated pharmaceutical company. In addition to his deep industry knowledge, Dr. Deniz’s team-based approach and entrepreneurial spirit exemplify Flexion’s core values and make him an excellent fit for our company culture.”

    In February 2017, Flexion announced that the U.S. Food and Drug Administration (FDA) accepted the New Drug Application for Zilretta in osteoarthritis (OA) of the knee. Under the Prescription Drug User Fee Act (PDUFA), the agency has established a user fee goal date of October 6, 2017.

    About Flexion Therapeutics
    Flexion is a specialty pharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with OA. The company’s lead product candidate, Zilretta, is being investigated for its potential to provide improved analgesia for the millions of U.S. patients who receive intra-articular injections for OA-related knee pain annually.

    Click here to read the full press release.

    pharmaceutical investingge healthcarechief scientific officerdrug candidatesflexion therapeuticschief medical officerfood and drug administration
    The Conversation (0)
    Go Deeper
    AI Powered
    Senior woman doing exercises alongside closeup of DNA.

    5 US Longevity and Anti-aging Stocks to Watch in 2025

    Canada maple leaves on left and pharmaceutical pills in red and blue on right.

    5 Best-performing Canadian Pharma Stocks (Updated January 2025)

    Latest News

    More News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Pharmaceutical Investing Stocks

    Invion Limited

     
    IVX:AU

    Cardiol Therapeutics

     
    CRDL:CA
    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×